

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-35. (Cancelled)

36. (Currently amended) A composition comprising:

a therapeutic component in a therapeutically effective amount, and

an efficacy enhancing component including a prostanoid, the efficacy enhancing component being provided in an effective amount to enhance the pharmacokinetic disposition of the therapeutic component and to enhance the movement of the therapeutic component across a lipid membrane, or a biological membrane under physiological conditions, the efficacy enhancing component being present in a complex with the therapeutic component and being selected from the group consisting of anionic polymers, fatty acids, and mixtures thereof, the complex remaining substantially intact in an aqueous environment, each of the enhanced effects being relative to the effect obtained with the therapeutic component without the efficacy enhancing component.

37. (Previously added) A composition of claim 36 wherein the efficacy enhancing component is present in an amount effective to enhance the permeability of the therapeutic component relative to the permeability of the therapeutic component without the efficacy enhancing component.

38. (Previously added) A composition of claim 36 wherein the therapeutic component comprises an alpha-2-adrenergic agonist.

39. (Previously added) A composition of claim 38 wherein the alpha-2-adrenergic component comprises a quinoxaline component.

40. (Currently amended) A composition of claim 39 wherein the quinoxaline component is selected from the group consisting of quinoxalines, salts thereof, and mixtures thereof, ~~(2-imidazolin-2-ylamino) quinoxaline, 5-bromo 6-(2-imidazolin-2-ylamino) quinoxaline, and quinoxaline derivatives mixtures thereof.~~

*Ex-
cont.*

41. (Currently amended) A composition of claim 36 wherein the therapeutic component is selected from the group consisting of N-methyl-D-aspartate NMDA antagonists, antibacterials, antihistamines, decongestants, antiinflammatories, antiparasitics, miotics, anticholinergics, adrenergics, antivirals, local anesthetics, antifungals, amoebicidals, trichomonocidals, analgesics, mydriatics, antiglaucoma drugs, carbonic anhydrase inhibitors, ophthalmic diagnostic agents, ophthalmic agents used as adjuvants in surgery, chelating agents, antineoplastics, antihypertensives, muscle relaxants, diagnostics, and mixtures thereof.

42. (Cancelled)

43. (Currently amended) A composition of claim 36 wherein the efficacy enhancing component is further comprises a fatty acid selected from the group consisting of saturated fatty acids and unsaturated fatty acids, and mixtures thereof.

44. (Currently amended) A composition of claim 36 wherein the efficacy enhancing component further comprises a fatty acid with more than 12 carbon atoms per molecule.

45. (Currently amended) A composition of claim 36 wherein the efficacy enhancing component further comprises a docosahexanoic acid.

*C1
C-x.
cont.*
46. (Currently amended) A composition of claim 36 wherein the efficacy enhancing component further comprises a linolenic acid.

47. (Previously added) A composition of claim 36 wherein the efficacy enhancing component has a therapeutic effect.

48. (Previously amended) A composition of claim 36 wherein the efficacy enhancing component is therapeutically active when complexed with the therapeutic component.

49. (Previously amended) A composition of claim 36 wherein the efficacy enhancing component is therapeutically active when the efficacy enhancing component is not complexed with the therapeutic component.

50. (Previously added) A composition of claim 36 wherein the efficacy enhancing component is effective to reduce

intraocular pressure when the composition is administered to the eye.

51. (Cancelled)

52. (Cancelled)

53. (Previously amended) A composition of claim 36 wherein the complex is insoluble.

54. (Previously added) A composition of claim 36 wherein the complex is dissociable in a biological environment to provide a therapeutic effect.
*C1
cont.*

55. (Previously added) A composition of claim 36 which includes at least one additional therapeutic component and the efficacy enhancing component is complexed with both the therapeutic component and the additional therapeutic component.

56. (Previously added) A composition of claim 36 wherein a single therapeutic component is present in the complex with more than one efficacy enhancing component.

57. (Previously added) A composition of claim 36 which is ophthalmically acceptable.

58. (Previously added) A composition of claim 36 which further comprises a carrier.

59. (Previously amended) A composition comprising:
an adrenergic agonist; and

a fatty acid selected from the group consisting of docosahexanoic acids, linolenic acids, and mixtures thereof,

wherein the adrenergic agonist is present in a complex with the fatty acid, the complex substantially remains intact in an aqueous environment.

60. (Currently amended) A composition comprising:

*E1
cont.*
a complex including a therapeutic component, and an efficacy enhancing component, wherein the efficacy enhancing component is selected from the group consisting of anionic polymers, fatty acids, and mixtures thereof, and is present in an amount effective to enhance the movement of the therapeutic component across a lipid membrane, or a biological membrane under physiological conditions, each of the enhanced effects being relative to the effect obtained with the therapeutic component without the efficacy enhancing component; and

a carrier component which includes saline.

, the complex comprising:

a therapeutic component, and

an efficacy enhancing component,

wherein the efficacy enhancing component is selected from the group consisting of anionic polymers, fatty acids, and mixtures thereof, and is present in an amount effective to enhance the movement of the therapeutic component across a lipid membrane, or a biological membrane under physiological conditions, each of the enhanced effects being relative to the effect obtained with the therapeutic component without the efficacy enhancing component.

61. (Previously added) A composition of claim 60 wherein the therapeutic component comprises an alpha-2-adrenergic agonist.

62. (Previously added) A composition of claim 61 wherein the alpha-2-adrenergic agonist includes a quinoxaline component.

63. (Currently amended) A composition of claim 62 wherein the quinoxaline component is selected from the group consisting of quinoxalines, salts thereof, and mixtures thereof, ~~(2-imidazolin-2-ylamine) quinoxaline, 5-bromo-6-(2-imidazolin-2-ylamine) quinoxaline, quinoxaline derivatives and mixtures thereof.~~

*C1
cont.*
64. (Currently amended) The composition of claim 60 wherein the therapeutic component is selected from the group consisting of N-methyl-D-aspartate ~~NMDA~~ antagonists, antibacterials, antihistamines, decongestants, antiinflammatories, antiparasitics, miotics, anticholinergics, adrenergics, antivirals, local anesthetics, antifungals, amoebicidals, trichomonocidals, analgesics, mydriatics, antiglaucoma drugs, carbonic anhydrase inhibitors, ophthalmic diagnostic agents, ophthalmic agents used as adjuvants in surgery, chelating agents, antineoplastics, antihypertensives, muscle relaxants, diagnostics, and mixtures thereof.

65. (Previously added) A composition of claim 60 which has a pH of about 7 or greater.

66. (Previously added) A composition of claim 60 which has a pH in a range of about 7 to about 9.

67. (Cancelled)

68. (Previously added) A composition of claim 60 which is ophthalmically acceptable.

69. (Cancelled)

70. (New) The composition of claim 39, wherein the quinoxaline component is selected from the group consisting of (2-imidazolin-2-ylamino) quinoxalines, salts thereof, and mixtures thereof.

E' cont.
71. (New) The composition of claim 39, wherein the quinoxaline component is selected from the group consisting of 5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline, salts thereof, and mixtures thereof.

72. (New) The composition of claim 62, wherein the quinoxaline component is selected from the group consisting of (2-imidazolin-2-ylamino) quinoxalines, salts thereof, and mixtures thereof.

73. (New) The composition of claim 62, wherein the quinoxaline component is selected from the group consisting of 5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline, salts thereof, and mixtures thereof.

74. (New) A composition comprising:

a therapeutic component in a therapeutically effective amount, the therapeutic component comprising a 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline, and

an efficacy enhancing component selected from the group consisting of docosahexanoic acids, linolenic acids, prostanoids, and mixtures thereof, the efficacy enhancing component provided in an effective amount to enhance the pharmacokinetic disposition of the therapeutic component and to enhance the movement of the therapeutic component across a lipid membrane, or a biological membrane under physiological conditions, the efficacy enhancing component being present in a complex with the therapeutic component, the complex remaining substantially intact in an aqueous environment, each of enhanced effects being relative to the effect obtained with the therapeutic component without the efficacy enhancing component.

*C |
C Cont.*

75. (New) The composition of claim 74, further comprising at least one additional therapeutic component selected from the group consisting of N-methyl-D-aspartate antagonists, antibacterials, antihistamines, decongestants, antiinflammatories, antiparasitics, miotics, anticholinergics, adrenergics, alpha-2-adrenergic agonists, antivirals, local anesthetics, antifungals, amoebicidals, trichomonocidals, analgesics, mydriatics, antiglaucoma drugs, carbonic anhydrase inhibitors, ophthalmic diagnostic agents, ophthalmic agents used as adjuvants in surgery, chelating agents, antineoplastics, antihypertensives, muscle relaxants, diagnostics, and mixtures thereof.

76. (New) The composition of claim 73, which has a pH of about 7 or greater.

E!
cancel

77. (New) The composition of claim 73, further comprising at least one additional efficacy enhancing component selected from the group consisting saturated fatty acids and unsaturated fatty acids, and mixtures thereof.
